**Supplementary Table 3.** Patient demographics and baseline characteristics in the French cohort of the CORRELATE study, stratified by ECOG PS.

|  |  |  |
| --- | --- | --- |
|  | **ECOG PS** |  |
|  | **0 (n=81)** | **1 (n=120)** | **>1 (n=20)** | **Missing (n=21)** | **Total (n=242)** |
| Age, median (range), years | 65 (39–86) | 67 (46–87) | 70.5 (49–83) | 60 (53–75) | 66 (39–87) |
| Male, n (%) | 51 (63.0) | 69 (57.5) | 14 (70.0) | 13 (61.9) | 147 (60.7) |
| ECOG performance status, n (%) |  |  |  |  |  |
| 0 | 81 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 81 (33.4) |
| 1 | 0 (0.0) | 120 (100.0) | 0 (0.0) | 0 (0.0) | 120 (49.6) |
| 2–4 | 0 (0.0) | 0 (0.0) | 20 (100.0) | 0 (0.0) | 20 (8.3) |
| missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 21 (100.0) | 21 (8.7) |
| *KRAS* mutation, n (%) |  |  |  |  |  |
| YesNoUnknown | 30 (37.0)49 (60.5)2 (2.5) | 63 (52.5)51 (42.5)6 (5.0) | 12 (60.0)6 (30.0)2 (10.0) | 6 (28.6)12 (57.1)3 (14.3) | 111 (45.9)118 (48.8)13 (5.4) |
| *BRAF* mutation, n (%) |  |  |  |  |  |
| YesNoUnknown | 4 (4.9)55 (67.9)22 (27.2) | 4 (3.3)78 (65.0)38 (31.7) | 2 (10.0)11 (55.0)7 (35.0) | 3 (14.3)12 (57.1)6 (28.6) | 13 (5.4)156 (64.5)73 (30.2) |
| NRAS mutation, n (%) |  |  |  |  |  |
| YesNoUnknown | 6 (7.4)37 (45.7)38 (46.9) | 6 (5.0)58 (48.3)56 (46.7) | 4 (20.0)7 (35.0)9 (45.0) | 2 (9.5)13 (61.9)6 (28.6) | 18 (7.4)115 (47.5)109 (45.0) |
| Main metastatic sites at regorafenib start, n (%) |  |  |  |  |  |
| liver | 64 (79.0) | 95 (79.2) | 15 (75.0) | 14 (66.7) | 188 (77.7) |
| lung | 54 (66.7) | 75 (62.5) | 15 (75.0) | 10 (47.6) | 154 (63.6) |
| peritoneum | 10 (12.4) | 15 (12.5) | 6 (30.0) | 4 (19.1) | 35 (14.5) |
| bone | 9 (11.1) | 9 (7.5) | 4 (20.0) | 1 (4.8) | 23 (9.5) |
| Time from diagnosis of metastatic disease to regorafenib start, median (range), months | 25.9 (1.6–115) | 28.3 (<1––169) | 28.2 (3–61) | 22.3 (10–75) | 27.0 (<1–169) |
| Prior systemic anti-cancer therapy, n (%) |  |  |  |  |  |
| yes | NA | NA |  |  | 240 (99.2) |
| no | NA | NA |  |  | 2 (0.8) |
| Number of prior systemic anti-cancer therapies, median (range) | NA | NA |  |  | 3 (1–12) |

ECOG PS – Eastern Cooperative Oncology Group performance status; NA: not available.